BREAKING
AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 11 hours ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 2 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 2 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 2 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 5 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 6 days ago Synopsys Q1 2026 Earnings Results 6 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 6 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 6 days ago AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 11 hours ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 2 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 2 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 2 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 5 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 6 days ago Synopsys Q1 2026 Earnings Results 6 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 6 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 6 days ago
ADVERTISEMENT
AlphaGraphs

Trxade Group (MEDS) delivers annual revenue growth of 130%

Trxade (NASDAQ: MEDS) on Monday posted a 17% increase in fourth-quarter revenues to $2 million, riding on the strength of the Trxade Platform and Trxade Prime. The top-line, however, missed the average Wall Street consensus.  Meanwhile, the company posted a wide net loss of $0.29 per share on goodwill impairment and inventory write-down, compared to […]

$MEDS March 29, 2021 1 min read
NYSE
$MEDS · Earnings

Trxade (NASDAQ: MEDS) on Monday posted a 17% increase in fourth-quarter revenues to $2 million, riding on the strength of the Trxade Platform and Trxade Prime. The top-line, however, missed the average Wall Street consensus.  Meanwhile, the company posted a wide net loss of $0.29 per share on goodwill impairment and inventory write-down, compared to […]

· March 29, 2021

Trxade (NASDAQ: MEDS) on Monday posted a 17% increase in fourth-quarter revenues to $2 million, riding on the strength of the Trxade Platform and Trxade Prime. The top-line, however, missed the average Wall Street consensus. 

Meanwhile, the company posted a wide net loss of $0.29 per share on goodwill impairment and inventory write-down, compared to analysts’ projection of EPS of $0.01.

Trxade Q4 2020 earnings

CEO Suren Ajjarapu said in a statement, “Despite the challenges of a global pandemic, we increased revenues by 130% for the year, a testament to our team’s continued innovation and development of our breakthrough digital healthcare services IT platform. ”

MEDS stock was up 2% during after-market hours on the stronger-than-expected revenues. The stock has gained 21% since the beginning of this year.

CEO TALKS: The story of Trxade Group (MEDS)

ADVERTISEMENT

In the fourth quarter, the Tampa, Florida-based firm added 328 new independent pharmacies to its network. The company now has over 11,800 registered pharmacy members.

Trxade, which brings together independent pharmacies under one umbrella through its web-based purchasing platform, is present in all 50 states and is rapidly adding pharmacies to its network.

___

Prior performance

  • Trxade Group Q3 2020 earnings
  • Trxade Group Q2 2020 earnings results.
  • Trxade Group Q1 2020 earnings

ADVERTISEMENT